Research & Reviews: Journal of Pharmacology and Toxicological Studies

Review on Type 1 Diabetics

Gourav N[1]*, Challa HY[2] and Ram Vinod ND[3]

[1]Vijaya college of Pharmacy, Hayatnagar, Hyderabad, India
[2]School of Pharmacy, University of Wolverhampton, UK
[3]Sri Krishna Devaraya University, Anantapur, Andhra Pradesh, India

Review Article

ABSTRACT

Type 1 Diabetes mellitus happens because of immune system obliteration of the insulin-creating beta cells in the pancreas. It is generally analyzed in kids and youthful grown-ups, and was beforehand known as juvenile diabetes. This sequential shortage of insulin creating beta cells results in expanded glucose levels in blood and pee. Just 5% of diabetic individuals have this type of the ailment. Indications incorporate successive pee, expanded thirst, expanded appetite, and weight reduction. Reason for Type 2 diabetes is obscure. The Autoantibody testing which measures endogenous insulin generation recognizes Type 1 from Type 2 diabetes. This survey depends on a pursuit of Diabetes Ireland, Home of the Daily and Sunday Express, and American diabetes affiliation.

INTRODUCTION

Diabetes mellitus is the soonest ailment known not, initially described around 3000 years back in Egyptian original copy [1]. In 1910 English physiologist Sir Edward Albert Sharpey-Schafer's studies on pancreas drives him to the location of a substance that is regularly created in non-diabetics i.e., Insulin. In 1916 Elliott Joslin, distributes the principal version of The Treatment of Diabetes Mellitus [2-5].

In 1959 Solomon Berson and Rosalyn Yalow propelled a system for measuring insulin in the blood using radioimmunoassay advancement [6-9]. Their studies saw that a couple people with diabetes still make their own specific insulin, and they are sorted as "insulin-ward" (Type 1) and "non-insulin-subordinate" (Type 2) diabetes [10-14].

In 1982 FDA endorsed human insulin delivered by hereditarily modified microscopic organisms. A 64k autoantibody is found and is found that it is connected with Type 1 diabetes [15].

In 2002 treatment with the counter CD3 monoclonal neutralizer, hOKT3gamma1 (Ala-Ala), moderates the devaluation of insulin creation and enhances metabolic control amid the main year of Type 1 diabetes in the lion's share of patients [16-21].

STUDY OF DISEASE TRANSMISSION

Just 5%-10% of diabetic individuals have this type of the malady. Internationally the quantity of individuals with Type 1 diabetes is obscure, despite the fact that it is assessed that around 80,000 youngsters build up the illness every year [22-25]. Inside the United States the quantity of influenced people is evaluated at one to three million [26-28]. Most of the DM load in Scandinavia has all the earmarks of being Type 1 DM, where rates are more like 35 new cases for each 100,000 every year [29,30].

Presentation to radiation expanded danger of both amiable and harmful thyroid sores holds on for no less than 3 decades past time of introduction [28-30]. Rapid enlargement, pain or tenderness over the nodule, dysphasia, dysphonia, or hoarseness is imperative clinical evaluation criteria's for suspicious knobs [31-35]. Fixture of knob, development with swallowing, provincial lymphadenopathy is additionally critical to evaluate thyroid knobs.

ADMINISTRATION, CARE AND SYMPTOMS

Administration by insulin infusions

Type1 diabetes can be taken care of with insulin infusions or with the utilization of an insulin pump.
A few sorts of insulin are accessible:

Fast acting begins working in 15 minutes. It crests around 1 hour subsequent to infusing it and keeps on working for 2 to 4 hours.

General or short-acting begins working in around 30 minutes. It crests somewhere around 2 and 3 hours and continues working for 3 to 6 hours.

Middle of the road acting doesn't go into circulation system for 2 to 4 hours after infusion. It crests from 4 to 12 hours and works for 12 to 18 hours.

Long-acting takes a few hours to go into circulation system and goes on for around 24 hours. Way of life changes Exercise has vital influence for treating sort 1. Be that as it may, it isn't as simple as going out for a run. You need to superbly adjust insulin dosage and the nourishment with any action, notwithstanding for basic and simple errands around the house [31-35].

After and before any movement check glucose to know how it influences you. Now and then the levels of insulin will levels go up; now and then won't [36-40]. In the event that the Insulin levels are too low have a nibble with carbs to avert it.

On the off chance that the test demonstrates elevated amounts of insulin, test for ketones acids that can come about because of high sugar levels. On the off chance that they're OK, you ought to be ready. In the event that they're high, avoid the workout [41].

One can assemble an adhering to a good diet arrangement in the event that he/she can see how sustenance influences glucose and the parts that carbs, fats, and protein play, and the levels where they ought to be [42-46].

What happens if type 1 diabetes left untreated

In the event that Type 1diabetes left untreated, it results in genuine or life-undermining issues:

Retinopathy: It influences around 80% of grown-ups who have Type 1diabetes for over 15 years. It's restricted before youthfulness regardless of to what extent you've had the ailment [47]. Keeping great control of glucose, circulatory strain, cholesterol, and triglycerides counteracts it [48].

Kidney harm: About 20% to 30% of individuals with Type 1diabetes influences with nephropathy [49-52]. It shows up 15 to 25 years after the onset of diabetes. It might prompt other serious issues like kidney disappointment and coronary illness.

It additionally brings about poor blood flow and nerve harm. Harmed nerves and solidified courses results in loss of sensation and absence of blood supply to the feet [53-56]. These outcomes in expanding odds of harm and makes it harder for open injuries and wounds to mend. Nerve harm can likewise bring about digestive issues like sickness, regurgitating, and loose bowels [57-61].

Novel Technology to treat Type 1 Diabetics

The organization, called Islexa dispatched by the Cell and Gene Therapy Catapult (CGT) and the U.K's. University of Aberdeen, created novel innovation to treat Type 1diabetes to invalidate the utilization of insulin infusions [62,63].

As indicated by a discharge from the University of Aberdeen, the organization will hope to create innovation which reinvents pancreatic tissue that has been given, transforming it into "completely utilitarian islets [64-68]."

"Kevin Docherty, an educator at the University of Aberdeen said that "Islets are organoids that deliver numerous hormones, including insulin [69-73], and gave islets are as of now adequately treating serious instances of Type 1diabetes.

The college said that the innovation could endeavor thousands more patients with Type 1diabetes the alternative of an "islet transplant" [74], which furnishes patients with glucose control that is both compelling and long haul, invalidate the utilization of insulin organization [75-80].

Islet transplantation can change the lives of patients with Type 1diabetes, and now and again can bring about long haul flexibility from insulin infusions with incredible glucose control [81-83].

Transforming skin cells into healthy pancreatic cells

Researchers have figured out how to supplant the harmed pancreatic cells in Type 1diabetic patients by transforming skin cells into sound pancreatic cells.

This achievement could spell the end to the drudgery of insulin infusions.
The U.S. research profits by a method that permits researchers to utilize a mixed drink of vitamins, qualities and different mixes to transform one sort of cell into another [84-90].

United into a mouse, these cells functioned admirably enough to prevent the creatures from building up the condition, the diary Nature Communications reports.
In spite of the fact that insulin-delivering cells have been made some time recently, the new system is speedier and more viable [91-95].
In future, a fragment of skin could be taken from a patient's arm and used to make trillions of solid pancreatic beta cells.
The treatment, which is not yet prepared for human use, would be gone for individuals with Type 1diabetes.

Converting stem cells to beta cells

A Major leap forward is changing over undifferentiated cells to beta cells that could speed epitomized cell substitution item advancement and exploration to cure Type 1diabetes which could bring the new trust.

Doug Melton has built up a technique for changing over human undifferentiated cells (both embryonic and non-embryonic sorts) into insulin-delivering beta cells in the lab. This new strategy will eminently accelerate the transformation procedure. Old lab strategies just can mostly finish the transformation procedure. In the wake of achieving a specific point, the youthful cells could just develop into completely working beta cells after implantation into creatures, and the last change took months to happen [96-100].

Dr Melton's new technique for driving the full transformation is a leap forward towards potential vast scale, fast creation of human beta cells. As of now, wellsprings of human beta cells are generally constrained to corpse givers. Once culminated, be that as it may, Dr Melton's change technique could exponentially expand the accessibility of human beta cells, speeding conveyance of novel T1D cell substitution treatments and quickening essential exploration on a cure for the sickness.

CONCLUSION

Type 1diabetes (T1D) is an immune system malady, while a cure for Type 1 diabetes has for some time been looked for. The World Health Organization advised not very far in the past that countless anticipated that would "demonstration now" by getting fit.

There is an enormous rising in the frequency of the ailment around the globe. Just radical way of life changes including customary practice and enhanced eating routine can keep its "unwavering walk" getting to be wild.

REFERENCES

1. Chunhua Chen, et al. Elevated Interleukin-17 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Biochem Physiol. 2016;5:206.

2. Inancli SS, et al. Evaluation of Thyroid Autoimmunity in Gestational Diabetes Mellitus. J Diabetes Metab. 2016;7:682.

3. Kedar Mehta and Paragkumar Chavda. Beat Diabetes: Are We Ready. Gen Med (Los Angeles). 2016.

4. Tagliente I, et al. Management and Treatment of Type 1 And 2 Diabetes: State of Art. Gen Med (Los Angeles). 2016.

5. Bayramova AN. Gastroenterological Diseases as a Complications of Type 2 Diabetes Mellitus. J Gastrointest Dig Syst. 2016;6:442.

6. Xiaomei Tang, et al. A Randomized Controlled Clinical Trial on the Treatment of Type 2 Diabetes with Depression by Wu Ling Capsule. J Clin Trials. 2016;6:273.

7. Hernandez HE, et al. Baseline Anemia Analysis of Hispanic Dialysis Patients with and without Type 2 Diabetes. J Mol Histol Med Physiol. 2016.

8. Mitchell S, et al. Women in Control: Pioneering Diabetes Self-Management Medical Group Visits in the Virtual World. J Clin Trials. 2016;6: 272.

9. Cheekurthy AJP. Prevalence of Type 2 Diabetes Mellitus among Women and the Associated Risk Factors. Journal of Nursing and Health Sciences.2016.

10. Wei Fang, et al. The Effect on Gut Microbiota Structure of Primarily Diagnosed Type 2 Diabetes Patients Intervened by Sancai Lianmei Particle and Acarbose: A Randomized Controlled Trial. J Clin Trials. 2016; 6: 270.

11. Hariom Yadav. Gut Microbiome Derived Metabolites to Regulate Energy Homeostasis: How Microbiome Talks to Host. Metabolomics. 2016;6:e150.

12. Mesquita C, et al. Effect of the Endoplasmic Reticulum Stress on Diabetes Mellitus Type 2 in Hypothalamic Cells. Endocrinol Metab Syndr. 2016;5:243.

13. Norouzi Z, et al. (2016) The Prevalence of Depression in Patients with Diabetes Mellitus Type II in the Shahid Rahimi Hospital of Khorramabad, Iran. Epidemiology (Sunnyvale). 2016;6: 249.

14. Sajida Parveen and Sadia Anjum. To Investigate Prevalence of Diabetes Type 1 and Type 2 in HCV Infected Individuals. Epidemiology (Sunnyvale) 2016;6: 246.

15. Zbigniew Szybia. Primary Prevention of Obesity and Type 2 Diabetes Mellitus. Epidemiology (Sunnyvale) 2016;6:243.

16. Demchuk MP, et al. Efficacy of Fetal Stem Cells Use in Complex Treatment of Patients With Insulin-resistant Type 2 Diabetes Mellitus. J Stem Cell Res Ther. 2016;6:342.

17. Cakir OO, et al. Visceral Fat Volume is a Better Predictor for Insulin Resistance than Abdominal Wall Fat Index in Patients with Prediabetes and Type 2 Diabetes Mellitus. Intern Med. 2016;6:220.

18. Raina SK (2016) From NHM to NPCDCS: Epidemiological Transition and Need for a National Program for Diabetes in India. J Metabolic Synd. 2016;5:204.

19. Ignacio AB, et al. Diabetes Mellitus and Neuromuscular Blockade: Review. J Diabetes Metab   2016;7:678.

20. Vaia Lambadiari, et al. Short Term, Low Dose Thyroxin Treatment of Euthyroid Patients with Type 2 Diabetes improves Peripheral Blood Flow and Overall Insulin Sensitivity. J Diabetes Metab. 2016;7:677.

21. Berezin AE (2016) Can Osteoprotegerin be a Target of Therapy in Type 2 Diabetes Mellitus?. Metabolomics. 2016;6:172.

22. Hayashi A and Suganuma N. Physical Activity for Gestational Diabetes Mellitus. Clinics Mother Child Health 2016;13:238.

23. Sunanda T, et al. Role of HbA1c at Admission on Severity and Functional Outcome of Ischemic Stroke in Patients with Diabetes Mellitus. J Neurol Neurophysiol. 2016;7:377.

24. Tracey A Hines and Sajeesh Kumar. Certified Electronic Health Records and Quality of Health Care in Type II Diabetes Mellitus Patients. J Health Med Inform.2016.

25. Tina L, et al. Diabetes Mellitus and Airway Obstruction: Is there an Association?. Adv Practice Nurs.2016.

26. Demirsoy IH, et al. TCF7L2 rs7903146 Gene Variation Is Associated with Risk of Type 2 Diabetes in Turkish Population. J Clin Med Genom. 2016;4:141.

27. Arash Nayeri, et al. Type 2 Diabetes Mellitus is an Independent Risk Factor for Postoperative Complications in Patients Surgically Treated for Meningioma. J Neurol Neurophysiol. 2016;7:368.

28. Merlo S, et al. Polymorphisms rs699 and rs4762 of the Angiotensinogen Gene and Progression of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus. J Diabetic Complications Med. 2016;1:107.

29. Kobashi C, et al. Diabetic ketoacidosis due to Simultaneous Acute-Onset Type 1 Diabetes and Graves Disease. J Diabetes Metab. 2016;7:671.

30. Xing Wu, et al. Development of Type-2 Diabetes Mellitus is associated with Low Levels of ApoA1. J Diabetes Metab. 2016;7:669.

31. Kurioka S, et al. Combination Therapy of Pitavastatin and Sitagliptin Improves the Estimated Glomerular Filtration Rate in Patients with Type 2 Diabetes. J Diabetes Metab. 2016;7:667.

32. Wamique M and Ali W. CETP Gene and Its Role in Diabetes Mellitus Type II - A Review. J Community Med Health Educ. 2016;6:425.

33. Johnathan Jernigan and Sonia Lott. Inpatient Diabetes and the Pharmacist Role. RRJHCP.2016.

34. Abdulrhman MA. Honey as a Sole Treatment of Type 2 Diabetes Mellitus. Endocrinol Metab Syndr. 2016; 5: 232.

35. Jena PK, et al. Influence of Gut Microbiota on Inflammation and Pathogenesis of Sugar Rich Diet Induced Diabetes. Immunome Res 2016;12:109.

36. Yanhui Lin, et al. Discussion of EZSCAN Parameters for Diabetes Screening in Chinese. Biochem Anal Biochem. 2016;5:263.

37. Nørgaard SK, et al. Prepregnancy Body Mass Index and Offspring Birth Weight in Women with Type 1 and Type 2 Diabetes. J Preg Child Health. 2016.

38. Shaker El-Sappagh and Mohammed Elmogy. A Decision Support System for Diabetes Mellitus Management. Diabetes Case Rep. 2016;1:102.

39. Siddique MAH, et al. Comparison of Antioxidative Effects of Biguanides and Sulfonylureas Monotherapy on Total Antioxidant Status in Newly-Diagnosed Patients with Type 2 Diabetes Mellitus. Diabetes Case Rep. 2016;1:104.

40. Yukari Yaguchi, et al. Objective Evaluation of Zonular Weakness: Measurement of Lens Movement at the Start of Capsulorhexis Using Extracted Porcine Eyes. J Clin Exp Ophthalmol. 2016;7: 541.

41. Gian Piero Carnevale Schianca, et al. Searching For Prediabetes before Diabetes. Gen Med (Los Angeles). 2016.

42. Li Li, et al. Impact of Major Depressive Disorder on Prediabetes by Impairing Insulin Sensitivity. J Diabetes Metab 2016;7:664.

43. Edson da Silva, et al. Diabetes Mellitus and Periodontitis: Molecular Interrelationships. J immuno Biol. 1: e102.

44. Piatkiewicz P, et al. Autoimmunity Markers in Patients with Type 2 Diabetes. J Clin Diabetes Pract. 2016;1: 107.

45. Alexander E Berezin. Impaired Immune Phenotype of Endothelial Cell-derived Micro Particles: The Missing Link between Diabetes-related States and Risk of Cardiovascular Complications?. J Data Mining Genomics Proteomics. 2016;7:2.

46. Neeta Raj Sharma and Gundu HR Rao. Diabetes Management: Expectations and Limitations. J Diabetes Metab. 2016;7:662.

47. Yoshiko Ota, et al. Prognostic Impact of Diabetes Mellitus on Colorectal Cancer. Biol Med (Aligarh) 2016;8:299.

48. Shrivastava SRLB,et al. Physical Inactivity and Development of Diabetes: An Association Worth to be Explored. Biol Med (Aligarh).2016;8:e124.

49. Pawe. Hypoglycemia in Elderly Type 2 Diabetes Patients. J Clin Diabetes Pract. 2016;1:e103.

50. Prashanth Prabhu and SP Shanthala. Efferent Auditory System Functioning and Speech Perception in Noise in Individuals with Type II Diabetes Mellitus. J Phonet and Audiol.2016.

51. Cambridge Dictionaries Online. Be at a crossroads.

52. Dall T, et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care. 2014;37:3172-3179.

53. Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149.

54. Delahanty LM, et al, Diabetes Prevention Program Research Group. Effects of weight loss, weight cycling, and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program. Diabetes Care. 2014;37:2738-2745.

55. Diabetes Prevention Program Research Group. HbA1c as a predictor of diabetes and as an outcome in the Diabetes Prevention Program: a randomized clinical trial. Diabetes Care. 2015;38:51-58.

56. Hsu WC, et al. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care. 2015;38:150-158.

57. Cefalu WT and Riddle MC. SGLT2 inhibitors: the latest "new kids on the block"! Diabetes Care. 2015;38:352-354.

58. Miller KM, et al. T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38:971-978.

59. Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes—considerations for attempts to prevent and reverse the disease. Diabetes Care.2015;38:979-988.

60. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care.2015;38:989-996.

61. Skyler JS. Prevention and reversal of type 1 diabetes—past challenges and future opportunities. Diabetes Care.2015;38:997-1007

62. Bell KJ, et al. Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care.2015;38:1008-1015.

63. Choudhary P, et al. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care.2015;38:1016.

64. Robertson RP. Islet transplantation for type 1 diabetes, 2015: what have we learned from alloislet and autoislet successes? Diabetes Care.2015;38:1030-1035.

65. Kowalski A. Pathway to artificial pancreas systems revisited: moving downstream. Diabetes Care.2015;38:1036-1043.

66. Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation.Science.2014;343:1235681.

67. Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care.2011;34:518-523.

68. Goldstein DE, et al. Tests of glycemia in diabetes. Diabetes Care. 2004;27:1761-1773.

69. Saudek CD, et al. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006;295:1688-1697.

70. Shapiro R, et al. Sites of nonenzymatic glycosylation of human hemoglobin A. J Biol Chem.1980;255:3120-3127.

71. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1989;12:365-368.

72. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.

73. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet.1998;352:854-865.

74. Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med.2008;359:1577-1589.

75. Nathan DM, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.

76. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:S62-S69.

77. Mbanya JC, et al. Presidents' statement on WHO recommendation on HbA1c for diabetes diagnosis. Diabetes Res Clin Pract. 2011;93:310-311.

78. Sacks DB. Diabetes mellitus. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. (6th edn). Rifai N, Horvath AR, Wittwer CT, Eds. St. Louis, Elsevier Saunders, in press.

79. Little RR, et al. NGSP Steering Committee. The National Glycohemoglobin Standardization Program: a five-year progress report. Clin Chem. 2001;47:1985-1992.

80. Little RR, et al. National Glycohemoglobin Standardization Program (NGSP) Steering Committee. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem. 2011;57:205-214.

81. Weykamp C, et al. The IFCC Reference Measurement System for HbA1c: a 6-year progress report. Clin Chem.2008;54:240-248.

82. Dagogo-Jack S. Pitfalls in the use of HbA$_1$(c) as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol. 2010;6:589-593.

83. Gallagher EJ, et al. Review of hemoglobin A(1c) in the management of diabetes. J Diabetes. 2009;1:9-17.

84. Pani LN, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care. 2008;31:1991-1996.

85. Herman WH. Are there clinical implications of racial differences in HbA1c? Yes, to not consider can do great harm! Diabetes Care.2016;39:1458-1461.

86. Selvin E. Are there clinical implications of racial differences in HbA1c? A difference, to be a difference, must make a difference. Diabetes Care.2016;39:1462-1467.

87. Tuttle KR, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37:2864-2883.

88. Cavagnolli G, et al. Factors affecting A1C in non-diabetic individuals: Review and meta-analysis. Clin Chim Acta. 2015;445:107-114.

89. English E, et al.The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia. 2015;58:1409-1421.

90. Kim C, et al. Association between iron deficiency and A1C levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care. 2010;33:780-785.

91. Ford ES, et al. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011;3:67-73.

92. Cohen RM and Smith EP. Frequency of HbA1c discordance in estimating blood glucose control. Curr Opin Clin Nutr Metab Care. 2008;11:512-517.

93. McCarter RJ, et al. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care.2004;27:1259-1264.

94. Sacks DB, et al. Gaps in the glycation gap hypothesis. Clin Chem.2011;57:150-152.

95. Lachin JM, Genuth S, Nathan DM, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes.2007;56:1913-1921.

96. Weykamp C, et al. Glycation rate of haemoglobins S, C, D, E, J and G, and analytical interference on the measurement of HbA1c with affinity chromatography and capillary electrophoresis. Clin Chem Lab Med. 2015;53:e207-e210.

97. Delpierrre G, et al. Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin. J Biol Chem 2004;279:27613-27620.

98. Camargo JL, Stifft J, Gross JL. The effect of aspirin and vitamins C and E on HbA1c assays. Clin Chim Acta. 2006;372:206-209.

99. Schnedl WJ, et al. Evaluation of conditions associated with glycated hemoglobin values below the reference range. Clin Lab.2007;53:179-181.

100.   Serratrice J, et al. Interference of dapsone in HbA1c monitoring of a diabetic patient with polychondritis. Diabetes Metab. 2002;28:508-509.